How much money does the new crown vaccine attract?

On August 29, Zhifei Biological released the 2021 semi-annual report, achieving operating income of 13.

Times of inoculation

According to the latest data from the National Health Commission, as of August 28, 31 provinces and the Xinjiang Production and Construction Corps had reported a total of 2.

From the perspective of the technical route of vaccine research and development, China's new crown vaccine research and development mainly includes five technical routes, namely inactivated vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines, recombinant protein vaccines and nucleic acid vaccines

Inactivated vaccines-Sinopharm Zhongsheng, Kexing Biological

The domestic companies that have deployed inactivated vaccines mainly include Sinopharm Group, China Biological (Sinopharm Zhongsheng) and Kexing Biological

On August 28, the China Biological Official Account announced that as of August 26, Sinopharm’s global production and supply of 1.

According to the revenue data for the first half of 2021 released by China Biopharmaceuticals, the associates and joint ventures as a whole have contributed a total of 7.

Picture: Kerlaifu

Recombinant protein vaccine-Zhifei Bio

On August 27th, Zhifei Biological issued an announcement to disclose the company’s phase III clinical trial data of the company’s recombinant coronavirus vaccine.

Although Zhifei Biological is "a little behind" in the process of launching the new crown vaccine, the vaccine can be described as rapid increase

Perhaps the key to rapid volume increase is Zhifei's strong sales ability

Adenovirus vector vaccine-Cansino

On August 27, Cansino released a semi-annual report.

On February 25, 2021, CanSino's type 5 adenovirus vaccine was approved for marketing conditionally in the country, and it has successively obtained emergency use authorizations from Mexico, Pakistan and other countries

In addition, CanSino also focused on the deployment of aerosol inhalation inoculation type new crown vaccine.

Picture: "The Lancet"-aerosol inhalation vaccination type new crown vaccine

Source: Cansino

mRNA——Fosun Pharmaceutical

On August 24, Fosun Pharma released the 2021 semi-annual report.

Picture: Fubitai enters Taiwan

Regarding the issue of Fubi's listing in Thailand, at the shareholders' meeting on July 14, Fosun Pharma stated that the FDA's review of Fubitai has been basically completed, the expert review has been passed, and the administrative approval stage is intensified

Of course, I am more confident about the listing of Fubi in Thailand.

summary

At present, the domestic production of new crown vaccines is gradually increasing.